Aleniglipron

DRUG4 trials

Sponsors

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Conditions

Chronic Weight ManagementObeseObesityObesity Type 2 Diabetes MellitusObesity, Overweight, or Chronic Weight ManagementOverweightType2 Diabetes MellitusWeight Loss

Phase 2

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

CompletedNCT06693843

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsObesity, Overweight, or Chronic Weight Management

Start: 2024-10-28End: 2026-07-09Updated: 2026-08-10

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Active, not recruitingNCT07400588

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsObese, Obesity, Obesity Type 2 Diabetes Mellitus +1

Start: 2025-12-01End: 2026-09-01Updated: 2026-04-27

Phase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

RecruitingNCT07654361

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsChronic Weight Management, Obesity, Overweight

Start: 2026-07-13End: 2028-11-01Target: 3600Updated: 2026-08-10

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

RecruitingNCT07654374

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsChronic Weight Management, Obesity, Overweight +1

Start: 2026-07-17End: 2028-11-01Target: 1100Updated: 2026-09-11

Related Papers

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine2026-06-05